The economics of treatment in early rheumatoid arthritis

Best Practice and Research: Clinical Rheumatology

Volumn 23, Issue 1, 2009, Pages 83-92

  Bansback, Nick ^a   Marra, Carlo A ^b   Finckh, Axel ^c   Anis, Aslam ^b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

biologics; cost effectiveness; DMARDs; economics; productivity

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; RITUXIMAB;

AMBULATORY CARE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EARLY INTERVENTION; EMPLOYABILITY; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; WORK DISABILITY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; EARLY DIAGNOSIS; HEALTH CARE COSTS; HUMANS;

EID: 60749102335     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2008.11.005     Document Type: Review

References (62)

1. Kavanaugh A. Economic consequences of established rheumatoid arthritis and its treatment. Best Pract Res Clin Rheumatol 21 5 (2007) 929-942
2. Dunlop D.D., Manheim L.M., Yelin E.H., et al. The costs of arthritis. Arthritis Care Res 49 1 (2003) 101-113
3. Landewe R.B.M., Boers M., Verhoeven A.C., et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 46 2 (2002) 347-356
4. Bansback N.J., Regier D.A., Ara R., et al. An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-[alpha] antagonists. Drugs 65 4 (2005) 473
5. Finckh A., Liang M.H., van Herckenrode C.M., and de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 55 6 (2006 Dec 15) 864-872
6. Goekoop-Ruiterman Y.P.M., de Vries-Bouwstra J.K., Allaart C.F., et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146 6 (2007 Mar 20) 406-415
7. Yelin E. Is early intervention worth it?. J Rheumatol Suppl. (2005 Jan) 7236-7238
8. Cohen J.T., Neumann P.J., and Weinstein M.C. Does preventive care save money? health economics and the presidential candidates. N Engl J Med 358 7 (2008 Feb 14) 661-663
9. Drummond M., Stoddart G., Labelle R., and Cushman R. Health economics: an introduction for clinicians. Ann Intern Med 107 1 (1987 Jul) 88-92
10. Michaud K., Messer J., Choi H.K., and Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 48 10 (2003 Oct) 2750-2762
11. Pugner K.M., Scott D.I., Holmes J.W., and Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 29 5 (2000 Apr) 305-320
12. Yelin E., and Wanke L.A. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 42 6 (1999 Jun) 1209-1218
13. Rat A., and Boissier M. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine 71 6 (2004 Nov) 518-524
14. Young A., Dixey J., Cox N., et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Br Soc Rheumatology (2000)
15. Kapetanovic M.C., Lindqvist E., Saxne T., and Eberhardt K. Orthopaedic surgery in patients with rheumatoid arthritis over 20 years: prevalence and predictive factors of large joint replacement. Ann Rheum Dis 67 10 (2008 Oct) 1412-1416
16. Pynsent P.B., Carter S.R., and Bulstrode C.J.K. The total cost of hip-joint replacement; a model for purchasers. J Public Health 18 2 (1996 Jun 1) 157-168
17. Verhoeven A., Bibo J., Boers M., et al. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumatoide Artritis. Rheumatology 37 10 (1998 Oct 1) 1102-1109
18. Van den Hout W., Goekoop-Ruiterman Y., Allaart C., et al. Cost-utility analysis of four treatment strategies for early rheumatoid arthritis: 2-year results of the best study. Ann Rheum Dis 65 (2006 Jul) 507-508
19. Mittendorf T., Dietz B., von der Schulenburg J., et al. Decreased resource utilization during long-term treatment with adalimumab in patients with long-standing RA. Arthritis Rheum 54 9 (2006 Sep) S115-S115
20. Kirwan J.R. Conceptual issues in scoring radiographic progression in rheumatoid arthritis. J Rheumatol 26 3 (1999 Mar) 720-725
21. Burton W., Morrison A., Maclean R., and Ruderman E. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond) 56 1 (2006 Jan 1) 18-27
22. Sokka T. Work disability in early rheumatoid arthritis. Clin Exp Rheumatol 21 Suppl. 31 (2003) S71-S74
23. Albers J.M. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Br Soc Rheumatology (1999)
24. Young A., Dixey J., Kulinskaya E., et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 61 4 (2002 Apr 1) 335-340
25. Lacaille D., Sheps S., Spinelli J.J., et al. Identification of modifiable work-related factors that influence the risk of work disability in rheumatoid arthritis. Arthritis Rheum 51 5 (2004) 843-852
26. Wolfe F., and Hawley D.J. The longterm outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 patients. J Rheumatol 25 11 (1998 Nov) 2108-2117
27. Eberhardt K., Larsson B., Nived K., and Lindqvist E. Work disability in rheumatoid arthritis-development over 15 years and evaluation of predictive factors over time. J Rheumatol 34 3 (2007 Mar) 481-487
28. Puolakka K., Kautiainen H., Pekurinen M., et al. Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial. Ann Rheum Dis 65 7 (2006 Jul 1) 899-904
29. Merkesdal S., Ruof J., Schoffski O., et al. Indirect medical costs in early rheumatoid arthritis. Arthritis Rheum 44 (2001) 528-534
30. Li X., Gignac M.A.M., and Anis A.H. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. Medical Care 44 4 (2006) 304
31. Yelin E., Trupin L., Katz P., et al. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 48 11 (2003) 3046-3054
32. Smolen J.S., Han C., Heijde D.V.D., et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 54 3 (2006) 716-722
33. van Vollenhoven R., Ferraccioli G., Breedveld F., et al. Effect of adalimumab combination therapy on work performance: Results from a companion study to PREMIER. Ann Rheum Dis 66 Suppl. 2 (2007 Jul) 192-192
34. Bejarano V., Quinn M., Conaghan P., et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 59 10 (2008 Oct 15) 1467-74
35. Emery P., Breedveld F.C., Hall S., et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372 9636 (2008 Aug 2) 375-382
36. Kavanaugh A., Han C., and Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol 31 5 (2004 May) 849-855
37. de Croon E.M., Sluiter J.K., Nijssen T.F., et al. Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 63 11 (2004 Nov 1) 1362-1367
38. Zhang W., Bansback N., Guh D., et al. Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. J Rheumatol 35 9 (2008 Sep) 1729-1736
39. Han C., Smolen J., Kavanaugh A., et al. Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis. Arthritis Care Res 59 4 (2008) 510-514
40. Puolakka K., Kautiainen H., Moettoenen T., et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 50 1 (2004) 55-62
41. Jacob-Tacken K.H.M., Koopmanschap M.A., Meerding W.J., and Severens J.L. Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Economics 14 5 (2005 May) 435-443
42. Nicholson S., Pauly M.V., Polsky D., et al. Measuring the effects of workloss on productivity with team production. Health Economics 15 2 (2006 Feb) 111-123
43. Torrance G.W. Measurement of health state utilities for economic appraisal. J Health Economics 5 1 (1986 Mar) 1-30
44. Bansback N., Harrison M., Brazier J., et al. Health state utility values: a description of their development and application for rheumatic diseases. Arthritis Rheum 59 7 (2008 Jun 24) 1018-1026
45. Bansback N., Marra C., Tsuchiya A., et al. Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis Rheum 57 6 (2007) 963-971
46. Symmons D., Mathers C., and Pfleger B. The global burden of rheumatoid arthritis in the year 2000. Criterion. 12. Available from:. http://aolsearch.aol.co.uk/aol/search?query = The%20global%20burden%20of%20rheumatoid%20arthritis%20in%20the%20year%20 2000&invocationType = sb_uk
47. Wolfe F., Michaud K., Gefeller O., and Choi H.K. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 48 6 (2003 Jun) 1530-1542
48. Tan M.C.Y., Regier D.A., Esdaile J.M., et al. Health economic evaluation: a primer for the practicing rheumatologist. Arthritis Rheum 55 4 (2006 Aug 15) 648-656
49. Stinnett A.A., and Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 18 2 (1998 Apr 1) S68-S80
50. Gyrd-Hansen D. Willingness to pay for a QALY: theoretical and methodological issues. PharmacoEconomics 23 5 (2005) 423
51. Griffith J., and Carr A. What is the impact of early rheumatoid arthritis on the individual?. Best Pract Res Clin Rheumatol 15 1 (2001) 77-90
52. Eberhardt K., Larsson B.M., and Nived K. Early rheumatoid arthritis-some social, economical, and psychological aspects. Scand J Rheumatol 22 3 (1993) 119-123
53. Feldman D.E., Bernatsky S., Haggerty J., et al. Delay in consultation with specialists for persons with suspected new-onset rheumatoid arthritis: a population-based study. Arthritis Rheum 57 8 (2007 Dec 15) 1419-1425
54. Donahue K.E., Gartlehner G., Jonas D.E., et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148 2 (2008 Jan 15) 124-134
55. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 19 (2006 May 17) 2275-2285
56. Choy E.H.S., Smith C., Doré C.J., and Scott D.L. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford) 44 11 (2005 Nov) 1414-1421
57. Buxton M., Drummond M., Van Hout B., et al. Modelling in economic evaluation: an unavoidable fact of life. Health Economics (1997) 6217-6227
58. Chen Y., Jobanputra P., Barton P., et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 10 42 (2006 Nov) iii-iv, xi-xiii, 1-229
59. Davies A, Cifaldi MA, Segurado OG, Weisman MH. Cost-Effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J Rheumatol in press.
60. Carol Black's review - Health work wellbeing. [cited 2008 Mar 19]. Available from:. http://www.workingforhealth.gov.uk/Carol-Blacks-Review/
61. Wolfe F., and Michaud K. A brief introduction to the National Data Bank for rheumatic diseases. Clin Exp Rheumatol 23 5 (2005) 168
62. Kirwan J.R. Links between radiological change, disability, and pathology in rheumatoid arthritis. J Rheumatol 28 4 (2001) 881-886